ORLANDO — Two studies failed to meet their primary endpoints but still suggest cardioprotective benefits with two common heart drugs in patients receiving two key breast cancer drugs. In the ...

New research suggests that a healthy microbiome before chemotherapy could help protect breast cancer patients against heart damage, or cardiotoxicity, as a result of cancer therapy. Researchers found ...

The addition of an angiotensin-converting enzyme (ACE) inhibitor did not decrease risk for chemotherapy-related cardiac damage in patients being treated for breast cancer and non-Hodgkin lymphoma (NHL ...

Compared with White patients, Black and Hispanic patients who receive anthracycline chemotherapy for treatment of cancer are at increased risk for cardiotoxicity. Black and Hispanic patients who ...

The blood pressure medication enalapril did not prevent cardiotoxicity among patients with cancer being treated with chemotherapy. The angiotensin-converting enzyme (ACE) inhibitor enalapril, a common ...

Incidence and outcome of pulmonary hypertension in myelofibrosis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a full text component.

Please provide your email address to receive an email when new articles are posted on . Patients with gastrointestinal cancers had significantly lower risk for death if they received fluoropyrimidine ...

Sometimes the unintended consequences of a treatment can seem worse than the disease. That's certainly the case for patients who develop chemotherapy-induced cardiotoxicity—a severe side-effect that ...

In patients with gastrointestinal cancers treated with fluoropyrimidine-based chemotherapy agents, better overall survival at 1 year offsets a small increase in their risk of CV events, new data ...

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on cardiotoxicity, explains Rakendu Rajendran, MBBS. At the ASPC 2025 Congress ...